Acumen pharmaceuticals to report first quarter results on may 14, 2024

Charlottesville, va., may 07, 2024 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos) (“acumen” or the “company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of alzheimer's disease, today announced that the company will report first quarter 2024 financial results on tuesday, may 14, 2024. the company will host a conference call and live audio webcast at 8:00 a.m. et to provide a business and financial update.
ABOS Ratings Summary
ABOS Quant Ranking